Toward in silico prediction of glass-forming ability from molecular structure alone: A screening tool in early drug development

Molecular Pharmaceutics

Volumn 8, Issue 2, 2011, Pages 498-506

  Mahlin, Denny ^a   Ponnambalam, Sopana ^a   Heidarian Höckerfelt, Mina ^a   Bergström, Christel A S ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

amorphous; glass forming ability; in silico models; molecular descriptors; prediction

Indexed keywords

ACETOHEXAMIDE; ALBENDAZOLE; GLASS; GRISEOFULVIN; HYDROCORTISONE; INDOMETACIN; INDOPROFEN; NAPROXEN; PHENYTOIN; PINDOLOL; PIROXICAM; PROBENECID; SPIRONOLACTONE; SULFAMERAZINE; TESTOSTERONE; TOLAZAMIDE; TOLFENAMIC ACID;

ARTICLE; CHEMICAL STRUCTURE; COMPUTER MODEL; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DEVELOPMENT; PRIORITY JOURNAL; X RAY DIFFRACTION;

CALORIMETRY, DIFFERENTIAL SCANNING; COMPUTER SIMULATION; COMPUTER-AIDED DESIGN; DISCRIMINANT ANALYSIS; DRUG DESIGN; GLASS; LEAST-SQUARES ANALYSIS; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79953809533     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100339c     Document Type: Article

References (32)

1. Wojnarowska, Z.; Grzybowska, K.; Adrjanowicz, K.; Kaminski, K.; Paluch, M.; Hawelek, L.; Wrzalik, R.; Dulski, M.; Sawicki, W.; Mazgalski, J.; Tukalska, A.; Bieg, T. Study of the Amorphous Glibenclamide Drug: Analysis of the Molecular Dynamics of Quenched and Cryomilled Material. Mol. Pharmaceutics 2010, 7, 1692-1707.
2. Trasi, N. S.; Boerrigter, S. X. M.; Byrn, S. R. Investigation of the Milling-Induced Thermal Behavior of Crystalline and Amorphous Griseofulvin. Pharm. Res. 2010, 27, 1377-1389.
3. Surana, R.; Pyne, A.; Suryanarayanan, R. Effect of preparation method on physical properties of amorphous trehalose. Pharm. Res. 2004, 21, 1167-1176.
4. Yamaguchi, T.; Nishimura, M.; Okamoto, R.; Takeuchi, T.; Yamamoto, K. Glass-Formation of 4″-O-(4-Methoxyphenyl)Acetyltylosin and Physicochemical Stability of the Amorphous Solid. Int. J. Pharm. 1992, 85, 87-96.
5. Bhugra, C.; Pikal, M. J. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J. Pharm. Sci. 2008, 97, 1329-1349.
6. Debenedetti, P. G.; Stillinger, F. H. Supercooled liquids and the glass transition. Nature 2001, 410, 259-267. (Pubitemid 32218700)
7. Adam, G.; Gibbs, J. H. On Temperature Dependence of Cooperative Relaxation Properties in Glass-Forming Liquids. J. Chem. Phys. 1965, 43, 139.
8. Dudowicz, J.; Freed, K. F.; Douglas, J. F. Entropy theory of polymer glass formation revisited. I. General formulation. J. Chem. Phys. 2006, 124.
9. Marsac, P. J.; Shamblin, S. L.; Taylor, L. S. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm. Res. 2006, 23, 2417-2426.
10. Taylor, L. S.; Zografi, G. Spectroscopic Characterization of Interactions Between PVP and Indomethacin in Amorphous Molecular Dispersions. Pharm. Res. 1997, V14, 1691-1698.
11. Pajula, K.; Taskinen, M.; Lehto, V. P.; Ketolainen, J.; Korhonen, O. Predicting the Formation and Stability of Amorphous Small Molecule Binary Mixtures from Computationally Determined Flory-Huggins Interaction Parameter and Phase Diagram. Mol. Pharmaceutics 2010, 7, 795-804.
12. Wang, R. Y.; Pellerin, C.; Lebel, O. Role of hydrogen bonding in the formation of glasses by small molecules: a triazine case study. J. Mater. Chem. 2009, 19, 2747-2753.
13. Alie, J.; Menegotto, J.; Cardon, P.; Duplaa, H.; Caron, A.; Lacabanne, C.; Bauer, M. Dielectric study of the molecular mobility and the isothermal crystallization kinetics of an amorphous pharmaceutical drug substance. J. Pharm. Sci. 2004, 93, 218-233.
14. Hancock, B. C.; Shamblin, S. L.; Zografi, G. Molecular Mobility of Amorphous Pharmaceutical Solids Below Their Glass-Transition Temperatures. Pharm. Res. 1995, 12, 799-806.
15. Bhattacharya, S.; Suryanarayanan, R. Local Mobility in Amorphous Pharmaceuticals-Characterization and Implications on Stability J. Pharm. Sci. 2009, 98, 2935-2953.
16. Zhou, D.; Zhang, G. G. Z.; Law, D.; Grant, D. J. W.; Schmitt, E. A. Physical stability of amorphous pharmaceuticals: Importance of configurational thermodynamic quantities and molecular mobility. J. Pharm. Sci. 2002, 91, 1863.
17. Graeser, K. A.; Patterson, J. E.; Zeitler, J. A.; Gordon, K. C.; Rades, T. Correlating thermodynamic and kinetic parameters with amorphous stability. Eur. J. Pharm. Sci. 2009, 37, 492-498.
18. Tang, X. L. C.; Pikal, M. J.; Taylor, L. S. A spectroscopic investigation of hydrogen bond patterns in crystalline and amorphous phases in dihydropyridine calcium channel blockers. Pharm. Res. 2002, 19, 477-483.
19. Marsac, P. J.; Konno, H.; Taylor, L. S. A comparison of the physical stability of amorphous felodipine and nifedipine systems. Pharm. Res. 2006, 23, 2306-2316.
20. Meunier, A.; Lebel, O. A Glass Forming Module for Organic Molecules: Making Tetraphenylporphyrin Lose its Crystallinity. Org. Lett. 2010, 12, 1896-1899.
21. Maria, T.; Lopes Jesus, A.; Eusébio, M. Glass-forming ability of butanediol isomers. Chem. Mater. Sci. 2010, 100, 385-390.
22. Lin, Y.; Cogdill, R. P.; Wildfong, P. L. D. Informatic calibration of a materials properties database for predictive assessment of mechanically activated disordering potential for small molecule organic solids. J. Pharm. Sci. 2009, 98, 2696-2708.
23. Baird, J. A.; Van Eerdenbrugh, B.; Taylor, L. S. A classification system to assess the crystallization tendency of organic molecules from undercooled melts. J. Pharm. Sci. 2010, 99, 3787-3806.
24. Jain, N.; Yalkowsky, S. H. Estimation of the aqueous solubility I: Application to organic nonelectrolytes. J. Pharm. Sci. 2001, 90, 234-252.
25. Wassvik, C. M.; Holmen, A. G.; Draheim, R.; Artursson, P.; Bergström, C. A. S. Molecular characteristics for solid-state limited solubility. J. Med. Chem. 2008, 51, 3035-3039.
26. Savolainen, M.; Kogermann, K.; Heinz, A.; Aaltonen, J.; Peltonen, L.; Strachan, C.; Yliruusi, J. Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy. Eur. J. Pharm. Biopharm. 2009, 71, 71-79.
27. Bergström, C. A. S.; Wassvik, C. M.; Johansson, K.; Hubatsch, I. Poorly soluble marketed drugs display solvation limited solubility. J. Med. Chem. 2007, 50, 5858-5862.
28. Höckerfelt, M. H.; Nyström, C.; Alderborn, G. Dry mixing transformed micro-particles of a drug from a highly crystalline to a highly amorphous state. Pharm. Dev. Technol. 2009, 14, 233-239.
29. Huttenrauch, R.; Fricke, S.; Zielke, P. Mechanical Activation of Pharmaceutical Systems. Pharm. Res. 1985, 302-306.
30. Heidarian Höckerfelt, M.; Alderborn, G. An approach to assess the disordering propensity of crystals during mechanical straining, Conference contribution; Drug Transport and Delivery; Gothenburg, 28-29 July, 2010.
31. Bergström, C. A. S.; Norinder, U.; Luthman, K.; Artursson, P. Molecular descriptors influencing melting point and their role in classification of solid drugs. J. Chem. Inf. Comput. Sci. 2003, 43, 1177-1185.
32. The Merck Index. http://www.medicinescomplete.com/mc/merck/current/ (14-01-2011).